ABCB1 and neoplasm: Furthermore, clinical trials using ABCB1 inhibitors to increase tumor uptake of chemotherapeutics had little success, partly because patients were not always screened for MDR status and partly because ABCB1 is not known to mediate MDR in some of the tested cancers [1, 11].